Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAURITE 2: Single- and repeat-dose IPN10200 for moderate to severe glabellar lines
2025-522618-22-00Phase 3Authorised
- Sponsor
- Ipsen
- Start
- Jun 2026
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of corabotase in glabellar furrowing (3 arms), sponsored by Ipsen. Primary endpoints: Primary efficacy (North America) and Primary efficacy (EU and rest of world). Planned start Jun 2026; status: authorised.
02
Drugs
corabotase
03
Conditions
glabellar furrowing
Beyond the preview
Go deeper on 2025-522618-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522618-22-00.